N/A N=148 STIM+: PET Biomarker Education & Disclosure
Mild Cognitive Impairment · Dementia; Alzheimer's Type (Etiology)
Primary: Participant Interest in PET Biomarker Disclosure — 73 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=155 Tau Screening Study in Patients With Early Symptomatic AD
Alzheimer Disease
Primary: Flortaucipir Qualitative Results (Visual Reads) — 56; 22; 78; 2 Participants
Phase 2 N=27 Practice Effects and Amyloid Imaging Using 18F-PIB or Flutemetamol PET and FDG-PET
Alzheimer's Disease
Primary: Amyloid Deposition Obtained on a 18F-flutemetamol Brain Scan. — 1.65 ratio of flutemetamol absorbed — p=<0.05
Phase 2 N=71 Imaging Tau in Alzheimer's Disease and Normal Aging
Alzheimer Disease
Primary: 18F-MK-6240 Binding — 1.41; 2.30 SUVr
Phase 2 N=161 Tau Screening Study in Subjects With Early Symptomatic AD
Alzheimer Disease
Primary: Flortaucipir Qualitative Results (Visual Reads) — 51; 13; 1; 65 Participants
Phase 2 N=28 Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals
Alzheimer's Disease
Primary: Differences in Standard Uptake Value Ratio (SUVR) for Frontal Cortex/Cerebellum and Whole Brain/Cerebellum of the Positron Emission Tomography (PET) Scan With…
Phase 3 N=223 Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects
Alzheimer's Disease
Primary: Confirmatory Phase: Relationship Between Neocortical Flortaucipir Uptake and the Subsequent Rate of Cognitive Decline — 36; 31; 27; 37 Participants — p=0.067
N/A N=10 Transmagnetic Stimulation Pilot in Early Stage Alzheimer's Disease
Alzheimer Disease
Primary: Change in Connectivity Measure of the TGd Parcellations. — 0.5 abnormal connections
N/A N=45 Non-invasive Stimulation of Brain Networks and Cognition in Alzheimer's Disease and Frontotemporal Dementia
Alzheimer's Disease · Frontotemporal Dementia, Behavioral Variant
Primary: Change in Clinical Disease Severity (CDR) — -0.1; 0.0; 0.0; 0.0 score on a scale
Phase 2 N=263 Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease
Alzheimer's Disease (AD)
Primary: Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog 14) Score at Week 12 — -1.26; -1.28; -1.68; -1.01 score on a scale — p=0.9819
Phase 2 N=20 Effect of Insulin Sensitizer Metformin on AD Biomarkers
Alzheimer's Disease · Vascular Dementia · Dementia
Primary: Word List Memory Total - ADAS-cog — 14.35; 14.7; 15.1; 14.67 Words recalled
Phase 2 N=109 Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.
Down Syndrome · Amyloid Beta-protein
Primary: Sensitivity of the Independent Visual Assessment of Detecting Cerebral Amyloid-beta in Individuals With Down Syndrome and Specificity in Subjects Without Down Syndrome…
Phase 2 N=125 Cognitive Decline and Alzheimer's Disease in the Dallas Lifespan Brain Study
Alzheimer Disease · Cognitive Decline
Primary: Standardized Uptake Value Ratios (SUVrs) Calculated From [18F]AV-1451 PET Scans — 1.09 standardized uptake value ratio
Phase 3 N=1,111 Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo
Alzheimer's Disease
Primary: Change From Baseline in Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog11) at 76 Weeks — 7.37; 6.77 units on a scale — p=0.560
Phase 3 N=1,169 Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Cognition Disorders
Primary: Change From Baseline of the Preclinical Alzheimer Cognitive Composite (PACC) Score — -1.43; -1.13 score on a scale — p=0.260
N/A N=160 Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172
Late Onset Alzheimer Disease
Primary: Relationship Between Cognitive Change Over Time and Amyloid (Aβ) Deposition — 41; 75 Participants — p=0.02
N/A N=78 Semantic Memory, Financial Capacity, and Brain Perfusion in Mild Cognitive Impairment (MCI) (CASL)
Alzheimer Disease · Dementia
Primary: FCI Score at Follow-up — 147.3; 164.0; 123.3; 150.8 points awarded for correct items
Phase 3 N=205 Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease
Alzheimer Disease
Primary: Risk Ratio for AD Symptom Progression on CDR-SB — 119; 43; 10; 5 Participants — p=0.0313
Phase 4 N=12 Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease
Alzheimer Disease
Primary: Changes in the Metabolite Ratios of N-acetylaspartate (NAA) to Creatine (Cr), Myo-inositol (mI) to Cr, Choline (Cho) to Cr, NAA to Cho, and NAA to mI, on Cholinesterase…
N/A N=9 Smell, Voice and Nasal Swabs as Markers for Neuro-degenerative Disorders
Alzheimer Disease · Neurodegenerative Diseases
Primary: Alpha-synuclein Levels From Nasal Swabs
Phase 1 N=13 [18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)
Alzheimer's Disease · Amnestic Mild Cognitive Impairment
Primary: Number of Participants With Adverse Events (AEs) — 1; 3; 2 Participants
N/A N=548 Evaluation of a Computerized Complex Instrumental Activities of Daily Living Marker (NMI)
Alzheimer Disease · Mild Cognitive Impairment · Memory Disorders
Primary: Change in Diagnostic Area Under the Receiver Operating Characteristic Curve (ROC-AUC) — 0.94; 0.91 probability
Phase 2 N=9 Imaging Inflammation in Alzheimer's Disease With 11C-ER176
Alzheimer Disease
Primary: 11C-ER176 Total Distribution Volume — 6.27; 9.32 mL/cm^3
Phase 2 N=80 Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease
Alzheimer's Disease
Primary: Change From Baseline (Day 1) in Global and Regional Indices of Cerebral Metabolic Rate of Glucose (CMRglu) at Month 12 — -0.2793; -0.0887; -0.3143; -0.0786 Milligrams…
Phase 2 N=16 Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG
Alzheimer Disease
Primary: Number of TEAEs, Related TEAEs, SAEs, and Related SAEs — 6; 11; 4; 7 Participants
Phase 2 N=100 The Synapse Project
Alzheimer Disease
Primary: ROC AUCs (MCI/AD vs Cognitively Unimpaired (CU)) for Medial Temporal Lobe (MTL) UCB-J Distribution Volume Ratio (DVR) and Hippocampal Volume — 0.79; 0.81 probability…
N/A N=10 tACS for Amyloid-β Reduction in Alzheimer's Disease
Alzheimer Disease
Primary: Change in Amyloid Burden — -1.55 dSUVR
N/A N=91 Dementia With Lewy Bodies - Infinitome
Dementia With Lewy Bodies
Primary: Functional Connectivity Scores Between Pairs of Large Scale Brain Networks. — 0.164; 0.374; 0.344; 0.340 connectivity score
Phase 2 N=36 Computerized Cognition Testing in Participants With Mild Alzheimer's Disease (AD) Treated With Donepezil (MK-0000-318)
Alzheimer's Disease
Primary: One-card Learning (OCL) Measurement Over 12 Weeks of Treatment — 0.954; 0.942; 0.822; 0.969 Score on a scale
Phase 2 N=23 Effect of CT1812 Treatment on Brain Synaptic Density
Alzheimer Disease
Primary: Number of TEAEs, Related TEAEs, SAEs, and Related SAEs — 7; 8; 6; 21 Participants